Answers are grounded in this paper and cite their sources.
Aim: To clarify the pharmacokinetics (PKs) of testosterone enanthate intramuscular injection in transgender men. Materials and Methods: This is a single-center nonblind single-drug administration study. After screening, 10 Japanese transgender men were administered 250 mg of testosterone enanthate intramuscularly. If the subjects had already received testosterone treatment, a screening test was carried out after washout for at least 4 weeks. The total testosterone (TT) and free testosterone (FT) and estradiol (E2) levels were examined for 4 weeks. At days 0 and 28, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were examined. Results: Mean age was 31.1 ± 7.2 years, and four subjects received first-time testosterone administration. Mean TT level at baseline was under the cutoff value in hypogonadal men. Mean time to reach its maximum level was 1.7 days, and in all cases within 3 days. Then, the level decreased and reached <3.0 ng/mL at day 21. Mean time to maximum level of FT was 3.4 days, but in three cases it was at day 7. The coefficient of variation in apparent total clearance and distribution volume for TT was large. The PK parameters of E2 could not be calculated in four cases. In the remaining six, E2 gradually decreased and reached the nadir at day 21. LH and FSH were not different before and after injection. No specific adverse event associated with testosterone administration was observed. Conclusions: PK profiles in transgender men after testosterone enanthate 250 mg single injection were clarified.
No takes yet. Share an insight, caveat, or question.
Ichihara et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: